FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL								
OMB Number:	3235-0287							
Estimated average burden								
hours per response	: 0.5							

	Check this box if no longer subject
\neg	to Section 16. Form 4 or Form 5
_	obligations may continue. See
	Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(b) of the Investment Company Act of 1940

						11011	00(11) 0	i tiic ii	IVCSUIICI	11 001	iipaiiy Act C	71 1540							
Name and Address of Reporting Person* Shefferman Jesse					2. Issuer Name and Ticker or Trading Symbol Protara Therapeutics, Inc. [TARA]								5. Relationship of Reporting Person(s) to Issuer (Check all applicable)						
Sherrer	<u>IIIdii Jes</u>	<u>se</u>						-1	,			•		X	Direc	ctor		10% Ov	vner
(Last)	(F	First) (Middle)				Trans	saction (N	/lonth	h/Day/Year)			X	Office below	er (give title v)		Other (s	specify	
C/O PROTARA THERAPEUTICS, INC.				06/23/2023									CEO and President						
345 PARK AVENUE SOUTH, 3RD FLOOR				4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable Line)							
(Ctt)														X	Form	n filed by Or	ne Rep	ortina Pers	on
(Street) NEW Y														Form filed by More than One Reporting Person					
(City)	(5	State) (:	Zip)		Rule 10b5-1(c) Transaction Indication														
						Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.													
		Table	I - No	n-Deriva	ive S	ecur	ities	Acq	uired,	Dis	posed of	f, or	Bene	ficiall	y Owr	ned			
1. Title of Security (Instr. 3) 2. Transact Date (Month/Day)				Executi y/Year) if any		ution Date,		Transaction Disp Code (Instr. 5)		Disposed	ecurities Acquired oosed Of (D) (Instr.		3, 4 and Secu Bene Own Follo		icially d ving	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership (Instr. 4)	
									Code	v	Amount	(A)	or P	rice		ed ction(s) 3 and 4)			
Common Stock 06/23/2					2023				G		1,890]	D S	\$0.00	911,873		D		
Common Stock 06/27/2					2023				G		7,420]	D S	\$0.00	904,453		D		
		Tal		Derivativ											Owne	ed			
		1	1		is, cai	is, v	varra	ınıs,	_					<u> </u>					
1. Title of Derivative Security (Instr. 3)	rative Conversion rity Date Execution Date, Conversion Date Execution Date, If any Conversion Conversion			tion Date,	4. Transaction Code (Instr. 8)				6. Date Exercisable and Expiration Date (Month/Day/Year)		te	7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and		De Se (In	Price of rivative curity str. 5)	9. Number derivative Securities Beneficiall Owned Following Reported Transactio (Instr. 4)	e O' s Fo lly Di oi (l)	10. Ownership Form: Direct (D) or Indirect I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
					Code	v	(A)	(D)	Date Exercisable		Expiration Date	Title	Amou or Numb of Share	er					

Explanation of Responses:

/s/ Jesse Shefferman

06/27/2023

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

^{*} If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

^{**} Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).